3.3 Secondary outcomes
death
The overall mortality rate was 11.2% (n = 11). Univariate analyses suggested non-significant differences between study groups for the outcome of all-cause mortality, although less patients in the Aggrenox group died compared to the control group (Aggrenox: 4 vs control: 7; p = 0.34). Furthermore, while not statistically significant, Kaplan-Meier analyses visually suggest an increasing trend of later death in the control group as day 28 was approached (